NASDAQ:ELDN Eledon Pharmaceuticals Q3 2026 Earnings Date & Estimates $2.41 +0.20 (+9.05%) Closing price 04:00 PM EasternExtended Trading$2.42 +0.01 (+0.25%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Eledon Pharmaceuticals is estimated to report Q3 2026 earnings on Friday, November 13, 2026. The conference call is scheduled for November 12, 2026 at 4:00 PM ET. Research:ProfileEarnings HistoryForecast Upcoming Earnings Announcement QuarterQ3 2026Announcement DateNovember 13, 2026Conference Call DateNovember 12, 2026Conference Call4:00 PM ET Add to CalendarGoogle Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab) What Analysts Expect from Eledon Pharmaceuticals in Q3 2026Eledon Pharmaceuticals is expected to post earnings of -$0.20 per share. In the same quarter a year earlier Eledon Pharmaceuticals reported -$0.21 per share. Eledon Pharmaceuticals last reported on August 13, 2026, posting -$0.27 per share and missing the -$0.1580 consensus estimate. Eledon Pharmaceuticals has beaten the consensus EPS estimate in 4 of its last 8 quarters.Consensus EstimatesConsensus EPS-$0.20Prior-Year EPS-$0.21Recent Track RecordLast ReportedQ2 2026Last Quarter EPS-$0.27 (Missed by -$0.1120)EPS Beat Rate4 of last 8 quartersPrepare for the Q3 2026 CallEarnings HistoryCompany ProfileQ2 2026 Earnings ReportQ1 2026 Earnings ReportQ4 2025 Earnings Report Eledon Pharmaceuticals Q3 2026 Earnings FAQ When does Eledon Pharmaceuticals report Q3 2026 earnings? Eledon Pharmaceuticals (NASDAQ:ELDN) is estimated to report Q3 2026 earnings on Friday, November 13, 2026. This date is estimated from past reporting schedules and may change once the company confirms it. What time is Eledon Pharmaceuticals' Q3 2026 earnings call? Eledon Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 4:00 PM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date. What is the consensus EPS estimate for Eledon Pharmaceuticals? Analysts expect Eledon Pharmaceuticals to post earnings of -$0.20 per share for Q3 2026. Eledon Pharmaceuticals Earnings HeadlinesEledon Pharmaceuticals, Inc. Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements In Quality Of Life And Symptom Burden With Tegoprubart Compared To Tacrolimus At ...October 26 at 6:34 PM | marketscreener.comMEledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at ...October 26 at 8:33 AM | markets.businessinsider.comFinancial legend: “This is bad, really bad...”Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.October 27 at 1:00 AM | Weiss Ratings (Ad)Eledon Pharmaceuticals Presents Phase 2 BESTOW Trial Data Showing Sustained Improvements in Quality of Life and Symptom Burden with Tegoprubart Compared to Tacrolimus at American Society of Nephrology Kidney Week 2026 Annual MeetingOctober 26 at 7:00 AM | globenewswire.comEledon Pharmaceuticals (NASDAQ:ELDN) Shares Climb 1.8% - Here's What HappenedOctober 23, 2026 | americanbankingnews.comEledon Pharmaceuticals Announces Presentation at the American Society of Nephrology Kidney Week 2026 Annual MeetingOctober 5, 2026 | globenewswire.comSee More Eledon Pharmaceuticals Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Eledon Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Eledon Pharmaceuticals and other key companies, straight to your email. Email Address About Eledon PharmaceuticalsEledon Pharmaceuticals (NASDAQ:ELDN) is a clinical-stage biopharmaceutical company focused on developing therapies that selectively modulate the immune system for patients with life-threatening diseases. The company’s research is centered on conditions involving immune activation, including organ transplantation, autoimmune disorders and other inflammatory diseases. Eledon’s lead product candidate is tegoprubart, a monoclonal antibody designed to block CD40 ligand, a protein involved in immune-system signaling. The company has evaluated tegoprubart in clinical programs involving kidney transplantation, islet-cell transplantation and amyotrophic lateral sclerosis, and continues to investigate its potential in transplantation and other immune-mediated conditions. The company was formerly known as Novus Therapeutics, Inc. and adopted the name Eledon Pharmaceuticals, Inc. in 2020. Eledon is headquartered in Irvine, California, and does not currently have a marketed commercial product; its activities primarily involve research, clinical development and collaboration with medical and scientific institutions.View Eledon Pharmaceuticals ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Apple's Foldable iPhone Sold Out in Minutes, But Wall Street Has QuestionsCoca-Cola Stock Is Everything AI Isn’t—And That’s Its Biggest StrengthWhirlpool's Stock Collapse Raises a Bigger Question About Its Recovery PotentialAnalysts Turn Bullish on Meta Platforms Despite Post-Earnings FallLockheed Martin's F-35 Deal Could Change How Wall Street Values the StockIntel's $155 Price Target Raises a Bigger Question About Its Turnaround PotentialMerck and Moderna's Cancer Vaccine Worked—Who Gets Paid? Upcoming Earnings Deutsche Bank Aktiengesellschaft (10/28/2026)UBS Group (10/28/2026)Mondelez International (10/29/2026)Starbucks (10/29/2026)Amazon.com (10/29/2026)Chevron (10/30/2026)BP (10/30/2026)Marriott International (11/2/2026)Vertex Pharmaceuticals (11/2/2026)Eaton (11/3/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
